Previous Article | Next Article 
Infection and Immunity, September 2000, p. 5126-5131, Vol. 68, No. 9
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Interleukin 18 Restores Defective Th1 Immunity
to Candida albicans in Caspase 1-Deficient
Mice
Antonella
Mencacci,1
Angela
Bacci,1
Elio
Cenci,1
Claudia
Montagnoli,1
Sabrina
Fiorucci,1
Andrea
Casagrande,1
Richard A.
Flavell,2
Francesco
Bistoni,1 and
Luigina
Romani1,*
Microbiology Section, Department of
Experimental Medicine and Biochemical Sciences, University of
Perugia, 06122 Perugia, Italy,1 and
Howard Hughes Medical Institute, Yale University School of
Medicine, New Haven, Connecticut 065102
Received 22 February 2000/Returned for modification 1 May
2000/Accepted 20 June 2000
 |
ABSTRACT |
Caspase 1, formerly designated interleukin 1
(IL-1
)-converting enzyme, processes pro-IL-1
and pro-IL-18 to
yield active cytokines that play a pivotal role in inflammation and
cell activation. We show here the effect of caspase 1 deficiency on the
inflammatory and adaptive immune responses to the fungus Candida
albicans. Caspase 1 deficiency did not affect susceptibility to
primary systemic infection with the fungus, as revealed by survival and fungal growth. However, Th1-mediated resistance to reinfection was
greatly impaired in caspase 1-deficient mice, and this correlated with
low-level production of IL-12 and gamma interferon. Early in infection,
production of these cytokines and that of tumor necrosis factor alpha,
IL-6, and, interestingly, IL-1
occurred normally in caspase
1-deficient mice, while that of IL-18 was severely impaired. Exogenous
administration of IL-18, more than IL-12, restored the Th1-mediated
resistance to the infection. We conclude that, while caspase 1 is not
indispensable for release of mature IL-1
in candidiasis, the caspase
1-dependent production of IL-18 may represent an important and novel
pathway for the expression of sustained Th1 reactivity to the fungus.
 |
INTRODUCTION |
Caspases, an expanding family of
cysteine proteases with a substrate specificity for aspartic acid, play
pivotal roles in inflammation and mammalian apoptotic cell death
(9, 11). The prototype, caspase 1, or interleukin 1
(IL-1
)-converting enzyme (8, 51), participates in the
cellular export of some proinflammatory cytokines, thus having a
prominent role in inflammation. Precursors of both IL-1
(8,
50) and IL-18 (16, 17, 23, 50) undergo proteolytic
cleavage by caspase 1, permitting the activated cytokines to exit the
cells. Peptide inhibitors of caspase 1 block IL-1
and IL-18 release
from activated macrophages in vitro (17). Caspase
1-deficient mice fail to exhibit elevated levels of IL-1
, IL-18, or
other proinflammatory cytokines, such as tumor necrosis factor alpha
(TNF-
), IL-1
, or IL-6, following lipopolysaccharide (LPS)
challenge. They are also resistant to LPS toxicity (24).
However, other enzymes, in addition to caspase 1, are able to cleave
pro-IL-1
and generate biologically active molecules (13,
53), including bacterial (4, 19) and fungal (3) enzymes. Thus, it appears that caspase 1 is not always indispensable for release of active IL-1
, but it is necessary for
the production of bioactive mature IL-18 (12, 13). Like IL-12, IL-18 promotes gamma interferon (IFN-
) production by Th1 and
natural killer cells in both mice and humans (reviewed in references
10 and 31) and increases Th1
resistance to infections (5, 20, 36, 52, 56). Unlike IL-12,
however, IL-18 by itself is unable to induce IFN-
(32)
and to drive Th1 development (37).
Previous studies showed that IL-12-induced IFN-
production is
essential for resistance to Candida albicans (28, 35,
38, 39, 46), the most frequently isolated fungal pathogen of
humans (30). In mucosal colonization and systemic infection
of mice with the fungus, Th1 cells mediate phagocyte-dependent
protection and are the principal mediators of acquired protective
immunity. In contrast, production of inhibitory cytokines such as IL-4
and IL-10 by Th2 cells and high levels of immunoglobulin E are
associated with disease progression (28, 35, 38, 39, 46).
Th2-like reactivity is frequently observed in patients with
Candida-related pathology, such as in symptomatic infections
(14, 35) and allergy (2). Th1-type responses may
thus characterize the carriage of saprophytic yeast and the resistance
to disease seen in healthy humans, whereas Th2 responses may be
associated predominantly with pathology.
In murine candidiasis, Th1 differentiation requires the combined
effects of different cytokines in the relative absence of counterregulatory cytokines, such as IL-4 and IL-10, which are, per se,
necessary and sufficient to drive Th2 polarization (25). Deficient IFN-
(6), transforming growth factor
(48), IL-6 (43), and TNF-
(26)
responses could each block the induction of protective immunity;
however, only IL-12 was both required and prognostic for the
development of protective Th1 responses to Candida (44,
45).
Because IL-18 synergizes with IL-12 for induction of Th1 cell
development (37, 49), in the present study we used caspase 1-deficient mice to assess (i) the patterns of proinflammatory and Th
cytokine production in C. albicans infection and (ii) the effect of exogenous IL-18 on IL-12 and IFN-
production and
resistance to the infection.
 |
MATERIALS AND METHODS |
Mice.
Caspase 1
/
mice were obtained as
previously described (17). Briefly, chimeric mice were
obtained by injection of embryonic stem cells, in which the caspase 1 gene was disrupted and replaced with a neomycin resistance cassette
gene, into C57BL/6 blastocysts. The chimeric males were then mated with
C57BL/6 mice. Homozygous mice with two copies of the disrupted caspase
1 gene were identified by Southern blotting of genomic DNA, and the
absence of caspase 1 mRNA in caspase 1
/
mice was
confirmed by reverse transcriptase PCR (RT-PCR) analysis. Homozygous
mice were then interbred and used for the experiments. Animals were
housed under specific-pathogen-free conditions at the breeding
facilities of the University of Perugia, Perugia, Italy. C57BL/6 mice,
6 to 8 weeks old, were obtained from Charles River (Calco, Italy).
(SV129 × C57BL/6)F1 mice, hereafter designated (SV129 × B6)F1, 6 to 8 weeks old, were obtained from
the Jackson Laboratory (Bar Harbor, Maine). For each experiment, groups
of mice were matched, as closely as possible, for sex and age.
Procedures involving animals and their care were conducted in
conformity with national and international laws and policies.
Yeasts, infections, in vivo analysis, and treatments.
The
origin and characteristics of the C. albicans low-virulence,
live vaccine strain PCA-2 and the high-virulence CA-6 strain used in
this study have been described in detail previously (6, 25,
42). For infection, yeast cells were washed twice in saline and
diluted to the desired density to be injected intravenously (i.v.) via
the lateral tail vein in a volume of 0.5 ml/mouse as previously
described (6, 25, 42). The viability of the cells was >95%
on trypan blue dye exclusion test and quantitative cultures. Resistance
to reinfection was assessed by injecting mice with 106
virulent Candida cells i.v. 14 days after primary infection. Mice succumbing to yeast challenge were routinely necropsied for histopathologic confirmation of disseminated candidiasis. Absolute numbers of neutrophils in peripheral blood were determined by total and
differential white cell counts. Quantification of yeast in the organs
of infected mice was performed by a plate dilution method, using
Sabouraud dextrose agar. Results were expressed as CFU per organ
(mean ± standard error [SE]). Recombinant murine IL-18 (rIL-18)
(R&D Systems Inc., Minneapolis, Minn.) or rIL-12 (Genetics Institute,
Cambridge, Mass.) was given intraperitoneally (i.p.) at the dose of 1 µg/injection or 10 ng/injection, respectively, on the day of primary
or secondary infection and 1 and 3 days later.
Purification and culture of cells.
CD4+ T
splenocytes were purified by using anti-mouse CD4-conjugated magnetic
MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany). Briefly,
107 total spleen cells were incubated with 100 µl of
magnetically activated cell-sorting CD4 MicroBeads for 15 min at 6°C,
washed, and magnetically separated with a positive selection column
(Miltenyi Biotec), according to the manufacturer's instructions.
Splenic macrophages were obtained by 2-h plastic adherence as
previously described (6, 27, 42). Peritoneal neutrophils
were collected 18 h after i.p. inoculation of aged, endotoxin-free
10% thioglycolate solution (Difco, Detroit, Mich.) as previously
described (40, 41). Unfractionated splenocytes or
CD4+ cells (10 × 106/ml) were cultured in
complete medium with 106 heat-inactivated C. albicans cells per ml for 48 h, before cytokine measurement
in culture supernatants. Irradiated splenocytes (2,000 rad) were added
(106/ml) to the CD4+ cultures as
antigen-presenting cells. In selected experiments, rIL-18 (50 ng/ml)
was added to the cultures of unfractionated splenocytes together with
rIL-2 (100 U/ml) as described previously (18).
Cytokine assays.
The levels of TNF-
, IL-6, IFN-
, and
IL-12 in culture supernatants were determined by means of
cytokine-specific enzyme-linked immunosorbent assay (ELISA), using
pairs of anticytokine monoclonal antibodies as previously described
(6, 27, 42). The monoclonal antibody pairs used were as
follows, listed by capture-biotinylated detection: TNF-
,
MP6-XT22-MP6-XT3; IL-6, MP5-20F3-MP5-32c11; and IFN-
,
R4-6A2-XMG1.2 (PharMingen, San Diego, Calif.). For IL-12p70
measurement, a modified antibody-capture bioassay was used
(48). The levels of IL-1
and IL-18 were determined using the specific ELISA kit (R&D Systems).
Candidacidal assay and NO production.
For the candidacidal
assay, 5 × 105 peritoneal neutrophils or splenic
macrophages were incubated with 5 × 104 PCA-2 cells
in 96-well flat-bottomed microtiter plates (Costar, Cambridge, Mass.)
for 1 or 4 h, respectively, and the number of CFU was determined
as described previously (7). The percentage of CFU
inhibition (mean ± SE) was determined as a percentage of colony
formation inhibition = 100
(CFU for experimental group/CFU for control cultures) × 100. Nitrite concentration, a measure of
nitric oxide (NO) synthesis, was assayed in culture supernatants by a
standard Griess reaction adapted to microplates, as described previously (7). The data represent the means ± SEs of
quadruplicate determinations and are expressed as micromolar
concentrations of NO2
per 107 cells.
RT-PCR.
RNA extraction and amplification of synthesized cDNA
from splenic adherent macrophages and purified CD4+
splenocytes were performed as previously described (6, 26, 27). For hypoxanthine-guanine phosphoribosyltransferase (HPRT), IL-12p40, IFN-
, IL-4, and IL-12 receptor
2 (IL-12R
2), the
primers and positive controls, cycles, and temperatures were as
previously described (6, 26, 27). For IL-18R, the primers
were synthesized using a 391 DNA synthesizer (PCR-MATE; Applied
Biosystems, Foster City, Calif.). The sequences of 5' sense primer and
3' antisense primer were as follows: sense,
5'-ATGTTGTCGTCTCCTTCCTG-3'; antisense, 5'-ATGTTGTCGTCTCCTTCCTG-3'. Each cycle consisted of 1 min at
94°C, 1 min at 60°C, and 1 min at 72°C. The HPRT primers were
used as a control for both reverse transcription and the PCR itself and also for comparing the amounts of products of samples obtained with the
same primer. The PCR fragments were analyzed by 1.5% agarose gel
electrophoresis and visualized by ethidium bromide staining.
PCR-assisted mRNA amplification was repeated at least twice for at
least two separately prepared cDNA samples for each experiment. Data
are representative of three different experiments.
Statistical analysis.
Survival data were analyzed using the
Mann-Whitney U test. Student's t test for unpaired data was
used to compare the fungal growth, the cytokine and NO production, and
the candidacidal activity. Significance was defined as P
0.05. In vivo groups consisted of four to six animals. Unless
otherwise specified, the data reported were pooled from three to five experiments.
 |
RESULTS |
Course of primary and secondary C. albicans infections
in caspase 1-deficient mice.
Caspase 1
/
and
C57BL/6 and (SV129 × B6)F1 mice, which have a genetic
background comparable with that of the caspase 1
/
mice,
were injected i.v. with 106 cells of low-virulence strain
PCA-2 or 105 cells of highly virulent C. albicans strain CA-6. For secondary infection, 14 days after
primary i.v. challenge, mice were i.v. injected with 106
cells of CA-6. The results (Table 1) show
that survival of the primary systemic infection with either PCA-2 or
CA-6 did not differ between caspase 1
/
mice and either
C57BL/6 or (SV129 × B6)F1 mice, each group of mice
having survived the PCA-2 infection while similarly succumbing to the
CA-6 infection. However, upon reinfection of mice surviving PCA-2
infection, C57BL/6 and (SV129 × B6)F1 mice survived
the infection, but caspase 1
/
mice did not.
Quantification of fungal growth in organs in the course of the
infection did not reveal major differences between mutant and wild-type
mice (data not shown). Similarly, histopathological examination of the
kidneys of PCA-2-infected mice revealed a slightly increased number of
foci of inflammatory reaction throughout the kidney parenchyma in
caspase 1
/
mice, compared to the few lesions observed
in the cortex of kidneys from (SV129 × B6)F1 mice
(data not shown). Therefore, these results suggest that effector
mechanisms of resistance to primary C. albicans infection
were not affected in caspase 1-deficient mice, which indeed efficiently
oppose infectivity in the initial stage of infection. However, caspase
1 deficiency appears to impair the development of acquired resistance
upon primary sublethal infection.
Antifungal effector functions are unimpaired in caspase 1-deficient
mice.
To assess the antifungal phagocytic response in caspase
1-deficient mice upon primary infection, caspase 1
/
and
C57BL/6 mice were infected i.v. with PCA-2 and the antifungal effector
functions of splenic macrophages and peritoneal neutrophils were
assessed 3 days after the infection. The results (Fig.
1) indicate that both types of cells were
equally activated to a candidacidal state in mutant and wild-type mice.
Similarly, neutrophils and, to a lesser extent, macrophages produced NO
upon exposure to C. albicans in vitro. We also determined
the number of circulating neutrophils 2 days after infection and found
that neutrophil counts increased in both types of mice upon infection,
being actually higher in caspase 1-deficient mice (from 361 ± 44 to 4,168 ± 380 in mutant mice and from 936 ± 89 to
2,980 ± 235 in wild-type mice). Therefore, innate antifungal
effector functions are unimpaired in caspase 1-deficient mice.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 1.
Antifungal effector functions of macrophages and
neutrophils from caspase 1 / (solid bars) and caspase
1+/+ C57BL/6 (open bars) mice, uninfected or upon primary
i.v. infection with C. albicans. Three days after infection,
splenic adherent macrophages and elicited peritoneal neutrophils were
assessed for their ability to kill yeast cells and to secrete NO in
vitro. Assays were done as described in Materials and Methods. *,
P < 0.05, caspase 1 / versus caspase
1+/+ mice.
|
|
Protective anticandidal Th1 responses are inhibited in caspase
1-deficient mice.
Protective acquired resistance to C. albicans correlates with the induction of CD4+ Th1
cells, producing IFN-
and expressing the IL-12R
2 (6, 26,
42). To assess the pattern of Th1 (IL-12 and IFN-
) and Th2
(IL-4) cytokine and IL-12R expression in caspase 1-deficient mice, mice
were infected i.v. with PCA-2 and reinfected with CA-6 14 days later.
Three days after reinfection, the expression of IL-12p40 (splenic
macrophages), IFN-
, IL-4, and IL-12R
2 (CD4+
T-lymphocyte) genes was assessed by RT-PCR for mutant and wild-type mice. Messages for IFN-
, IL-12p40, and IL-12R
2 were poorly
(IFN-
) or not (IL-12p40 and IL-12R
2) detected in caspase
1-deficient mice upon infection, as opposed to what was observed for
wild-type mice (Fig. 2). Moreover, the
IL-4 mRNA was detected in CD4+ cells from mutant but not
wild-type mice. Because the IL-18R was found to be selectively
expressed on Th1 but not Th2 cells (54), we also looked for
the IL-18R message in CD4+ splenocytes. No differences were
found in the expression of the message between mutant and wild-type
mice. These results indicate that susceptibility of caspase
1
/
mice to secondary C. albicans infection
correlates with the failure to induce the activation of Th1 cells and
the occurrence of IL-4-producing CD4+ Th2 cells.

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 2.
Cytokine and cytokine receptor gene expression in
caspase 1 / and caspase 1+/+ C57BL/6 mice
upon C. albicans infection. Mice were either uninfected
(lanes 1) or reinfected (lanes 2) with virulent CA-6, 14 days after the
primary infection with PCA-2. Levels of IFN- , IL-4, IL-12R 2, and
IL-18R mRNA (in CD4+ T splenocytes) and of IL-12p40 (in
splenic macrophages) were determined by RT-PCR, 3 days after
reinfection. C, HPRT- or cytokine- or cytokine receptor-specific
control. N, no DNA added to the amplification mix during PCR. M ,
macrophages.
|
|
Production of IL-18 is impaired in caspase 1-deficient mice
infected with C. albicans.
As the release of some
proinflammatory cytokines could be impaired in caspase 1-deficient mice
(16, 17, 23, 24) and production of TNF-
(26),
IL-6 (43), IFN-
(6), and IL-12 (27)
is required for the generation of anticandidal Th1 cell responses in
vivo, we assessed levels of these cytokines, together with those of
IL-1
and IL-18, in mutant and wild-type mice upon infection. As
early as 3 days after PCA-2 infection, the production of TNF-
, IL-6,
IL-12, and IFN-
was observed in caspase 1-deficient mice at levels
similar to those observed for wild-type mice (Fig. 3). IL-1
was produced in wild-type
mice and, interestingly, even in mutant mice. However, IL-18 could not
be detected in the latter mice as opposed to wild-type mice (Fig. 3),
despite the presence of the IL-18 message (data not shown). Both
cytokines were detected in culture supernatants of purified neutrophils
and macrophages from wild-type infected mice upon stimulation with
IFN-
and LPS in vitro (data not shown). These results suggest that,
early in infection, production of proinflammatory cytokines, including IL-12 and IFN-
, was not affected in caspase 1-deficient mice upon
C. albicans infection. In contrast, a defective production of IL-18 was observed.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 3.
Production of proinflammatory cytokines in caspase
1 / (solid bars) and caspase 1+/+ (open
bars) mice uninfected or infected with C. albicans. Mice
were i.v. infected with 106 PCA-2 cells and assessed 3 days
later for cytokine production in culture supernatants of
antigen-stimulated splenocytes. Levels of cytokines were determined by
means of cytokine-specific ELISA. Cytokine levels in culture
supernatants of unstimulated responder cells were below the detection
limit of the assay, indicated by < in the y axis. *,
P < 0.05, caspase 1 / versus caspase
1+/+ mice.
|
|
Exogenous IL-18 restores antifungal resistance and IFN-
and
IL-12p70 production in caspase 1-deficient mice.
To assess whether
IL-18 deficiency is responsible for the impaired anticandidal Th1
reactivity in caspase 1-deficient mice, exogenous rIL-18 was
administered to mutant mice infected with PCA-2. The cytokine was given
either at the time of the primary infection with PCA-2 or at the time
of the secondary infection with CA-6. For comparison, exogenous rIL-12
was similarly administered to infected mice. Mice were monitored for
resistance to the secondary infection, in terms of fungal growth in the
kidneys and production of IFN-
and IL-12. The results (Table
2) show that the fungal load was
significantly decreased in mice treated with rIL-18, at the time of
primary or secondary infection. Moreover, the production of IFN-
by
CD4+ T cells and that of IL-12p70 by splenocytes were
significantly increased in treated, compared to untreated, mice.
Similar results, although to a lesser extent, were obtained upon
treatment with rIL-12 at the time of the secondary infection. The
failure of earlier treatment with rIL-12 to increase Th1-mediated
resistance to reinfection is a finding in line with previous results
(44). In vitro, rIL-18 also increased IFN-
and IL-12
production by antigen-activated splenocytes from caspase 1-deficient
mice upon reinfection, particularly in the presence of IL-2. Such an
increase was not observed upon antigen activation of splenocytes from
nonvaccinated mice, upon infection with virulent CA-6 cells (Table
3). These results suggest that rIL-18
restores the Th1-mediated resistance of caspase 1-deficient mice to
C. albicans infection, an activity that cannot be fully
compensated for by exogenous rIL-12. In addition, it appears that
memory rather than naive Th cells are more susceptible to the ability
of IL-18 to promote IFN-
production. Therefore, IL-18 plays an
important role in maintaining sustained IFN-
and IL-12 production in
mice with C. albicans infection.
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Effect of rIL-18 on IFN- and IL-12 production by
C. albicans-stimulated cells from naive or vaccinated mice
|
|
 |
DISCUSSION |
In the present study, the use of caspase 1-deficient mice has
provided us with new insights into the cytokine-dependent regulation of
immunity to C. albicans. The major findings are, firstly,
that production of IL-18 is required for sustained expression of Th1 protective immunity to the fungus and, secondly, that caspase 1 activity is not necessary for the production of mature IL-1
, as it
is for mature IL-18.
Studies performed on caspase 1 (12, 13, 17, 23, 24)- or
IL-18 (49, 52)-deficient mice have revealed an essential role for IL-18 in IFN-
production in models of infection and inflammation. Despite normal (13) or even higher
(52) levels of IL-12 production, reduced levels of IFN-
were observed in caspase 1-deficient mice after stimulation with LPS
(10, 12, 13) or in IL-18-deficient mice upon infection with
intracellular or extracellular pathogens (52). Although
IL-18 and IL-12 exerted a synergistic effect on IFN-
production by
Th1 cells (1, 55), IL-18 also acted as an IL-12-independent
regulator of IFN-
production (21) and of cell
proliferation induced by microbial stimuli (13). Indeed, in
the absence of IL-18, IL-12 alone was insufficient for the induction of
Th1 cell expansion in vivo (49, 52). Furthermore, it has
recently been demonstrated that IL-18R is selectively expressed on
murine Th1, but not Th2, cells (54, 55). Therefore, although
IL-18, unlike IL-12, was unable to drive Th1 cell expansion in vitro
(37), these results clearly indicate that IL-18 has a direct
and profound effect on the activation and development of Th1 cells in
vivo. The results of the present study confirm this notion, by clearly
showing that IL-18 is required for sustained production of IFN-
and
IL-12 in C. albicans infection. Acquired immunity to the
fungus relied on the induction of protective Th1 cells producing
IFN-
and expressing the IL-12R
2. Although caspase 1-dependent
IL-18 production was not required for IFN-
production after
concanavalin A stimulation (13), IL-18 sustained the
expression of the IL-12R
2 mRNA (54). Thus, IL-18R may
transmit signals that maintain antifungal Th1 development through the
IL-12R complex. As in turn IL-12 up-regulates the expression of the
IL-18R (55), the synergistic effect of IL-12 and IL-18 on
Th1 development may rely on the reciprocal regulation of their
receptors. However, the expression of the IL-18R gene was not impaired
in caspase 1-deficient mice upon C. albicans infection, nor
in IL-12-deficient mice after infection (data not shown). These
findings indicate that factors other than IL-12 may regulate the IL-18R
mRNA in C. albicans infection.
Production of proinflammatory cytokines, including IFN-
and IL-12,
occurred normally in caspase 1-deficient mice early in infection, a
finding suggesting that the early cytokine response in C. albicans infection is relatively independent of caspase 1 processing of pro-IL-18. This observation is apparently at variance with what was observed in an experimental model of cryptococcosis, in
which the protective efficacy of IL-18 alone (20) or
combined with IL-12 (36) was seen early on but not at 3 to 6 weeks after infection and was dependent on IFN-
production by
stimulated NK cells (56). It appears that differences in the
relative contributions of various effector mechanisms in the host
defense against each fungal pathogen may determine the outcome of
treatment with IL-18.
One important observation of the present study is that production of
IL-1
was observed in caspase 1-deficient mice infected with C. albicans. That caspase 1 is not always required for release of
active IL-1
and that the requirement for caspase 1 in IL-1
processing is stimulus dependent has already been reported (13, 53). In particular, the finding that IL-1
is produced in
caspase 1-deficient mice after C. albicans infection
suggests that proteinases secreted by C. albicans may play
an important role in IL-1
processing, as already demonstrated
(3). In this regard, it is worth mentioning that proteinases
are produced by the PCA-2 C. albicans strain used in the
present study, particularly during infection (F. de Bernardis, personal communication).
It has been suggested that C. albicans proteinases may
contribute to the inflammatory nature of mucosal candidiasis by local activation of inflammatory IL-1
(3). In our study,
caspase 1
/
mice were not overtly more susceptible than
wild-type mice to gastrointestinal C. albicans infection
(data not shown). This finding would suggest a nonessential role of
IL-1
in the pathogenesis of mucosal candidiasis, even though local
production of IL-1
was not measured in caspase 1-deficient mice with
gastrointestinal infection. Instead, production of IL-1
was observed
in the course of disseminated infection with low-virulence C. albicans, a finding that confirms the protective effect that
IL-1
may have in infection (34).
Given the involvement of caspase 1 and IL-18 in inflammatory (15,
29) and noninflammatory (47) disease and the growing importance of IL-18 in the induction of optimal host immune defenses against pathogens (22, 31) and tumors (33), the
present study provided us with important insights into the caspase
1-dependent IL-18 production in mice with candidiasis. As the
experimental model adopted in the present study closely mimics the
state of long-lived commensalism with the fungus and the ensuing
immunity to it (35, 46), it appears that IL-18 meets the
requirement of a candidate cytokine which is required for sustained
expression of anticandidal Th1 immunity in self-limiting infection and saprophytism.
 |
ACKNOWLEDGMENTS |
This study was supported by the National Research Project on
AIDS, contract 50B.33, "Opportunistic Infections and Tuberculosis," Italy.
We thank Jo-Anne Rowe for editorial assistance. The murine rIL-12 was
supplied by the Bioanalytical Sciences Department of Genetics Institute
Inc., Cambridge, Mass.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Microbiology
Section, Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Via del Giochetto, 06122 Perugia, Italy. Phone
and fax: 39-075-5857411. E-mail: lromani{at}unipg.it.
Editor:
R. N. Moore
 |
REFERENCES |
| 1.
|
Ahn, H.,
S. Maruo,
M. Tomura,
J. Mu,
T. Hamaoka,
K. Nakanishi,
S. Clark,
M. Kurimoto,
H. Okamura, and H. Fujiwara.
1997.
A mechanism underlying synergy between IL-12 and IFN- -inducing factor in enhanced production of IFN- .
J. Immunol.
159:2135-2141.
|
| 2.
|
Akiyama, K.,
T. Shida,
H. Yasueda,
Y. Yanagihara,
M. Hasegawa,
Y. Maeda,
T. Yamamoto,
K. Takesako, and H. Yamaguchi.
1996.
Allergenicity of acid protease secreted by Candida albicans.
Allergy
51:887-892[Medline].
|
| 3.
|
Beauséjour, A.,
D. Grenier,
J. P. Goulet, and N. Deslauriers.
1998.
Proteolytic activation of the interleukin-1 precursor by Candida albicans.
Infect. Immun.
66:676-681[Abstract/Free Full Text].
|
| 4.
|
Black, R. A.,
S. R. Kronheim,
M. Cantrell,
M. C. Deeley,
C. J. March,
K. S. Prickett,
J. Wignall,
P. J. Conlan,
D. Cosman,
T. P. Hopp, and D. Y. Mocnizuki.
1988.
Generation of biologically active interleukin-1 beta by proteolytic cleavage of the inactive precursor.
J. Biol. Chem.
263:9437-9442[Abstract/Free Full Text].
|
| 5.
|
Bohn, E.,
A. Sing,
R. Zumbihl,
C. Bielfeldt,
H. Okamura,
M. Kurimoto,
J. Heeseman, and I. B. Autenrieth.
1998.
IL-18 (IFN- -inducing factor) regulates early cytokine production in, and promotes resolution of, bacterial infection in mice.
J. Immunol.
160:299-307[Abstract/Free Full Text].
|
| 6.
|
Cenci, E.,
A. Mencacci,
G. Del Sero,
C. Fè d'Ostiani,
P. Mosci,
M. Kopf, and L. Romani.
1998.
IFN- is required for IL-12 responsiveness in mice with Candida albicans infection.
J. Immunol.
161:3543-3550[Abstract/Free Full Text].
|
| 7.
|
Cenci, E.,
L. Romani,
A. Mencacci,
R. Spaccapelo,
E. Schiaffella,
P. Puccetti, and F. Bistoni.
1993.
Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of Candida albicans.
Eur. J. Immunol.
23:1034-1038[Medline].
|
| 8.
|
Cerretti, D. P.,
C. J. Kozlosky,
B. Mosley,
N. Nelson,
K. Van Ness,
T. A. Greenstreet,
C. J. March,
S. R. Kronheim,
T. Druck,
L. A. Cannizzaro,
K. Heubner, and R. A. Black.
1992.
Molecular cloning of the interleukin-1 -converting enzyme.
Science
256:97-100[Abstract/Free Full Text].
|
| 9.
|
Cohen, G. M.
1997.
Caspases: the executioners of apoptosis.
Biochem. J.
326:1-16.
|
| 10.
|
Dinarello, C. A.,
D. Novick,
A. J. Puren,
G. Fantuzzi,
L. Shapiro,
H. Mühl,
D.-Y. Yoon,
L. L. Reznikov,
S.-H. Kim, and M. Rubinstein.
1998.
Overview of interleukin-18: more than an interferon- inducing factor.
J. Leukoc. Biol.
63:658-664[Abstract].
|
| 11.
|
Elkon, K. B.
1999.
Caspases: multifunctional proteases.
J. Exp. Med.
190:1725-1728[Free Full Text].
|
| 12.
|
Fantuzzi, G.,
G. Ku,
M. W. Harding,
D. J. Livingston,
J. D. Sipe,
K. Kuida,
R. A. Flavell, and C. A. Dinarello.
1997.
Response to local inflammation of IL-1 -converting enzyme deficient mice.
J. Immunol.
158:1818-1824[Abstract].
|
| 13.
|
Fantuzzi, G.,
A. J. Puren,
M. W. Harding,
D. J. Livingston, and C. A. Dinarello.
1998.
Interleukin-18 regulation of interferon- production and cell proliferation as shown in interleukin-1 -converting enzyme (caspase-1)-deficient mice.
Blood.
91:2118-2125[Abstract/Free Full Text].
|
| 14.
|
Fidel, P. L., Jr., and J. D. Sobel.
1994.
The role of cell-mediated immunity in candidiasis.
Trends Microbiol.
16:202-206.
|
| 15.
|
Furlan, R.,
G. Martino,
F. Galbiati,
P. L. Poliani,
S. Smiroldo,
A. Bergami,
G. Desina,
G. Comi,
R. Flavell,
M. S. Su, and L. Adorini.
1999.
Caspase-1 regulates the inflammatory process leading to autoimmune demyelination.
J. Immunol.
163:2403-2409[Abstract/Free Full Text].
|
| 16.
|
Ghayur, T.,
S. Banerjee,
M. Hugunin,
D. Butler,
L. Herzog,
A. Carter,
L. Quintal,
L. Sekut,
R. Talanian,
M. Paskind,
W. Wong,
R. Kamen,
D. Tracey, and H. Allen.
1997.
Caspase-1 processes IFN- -inducing factor and regulates LPS-induced IFN- production.
Nature
386:619-623[CrossRef][Medline].
|
| 17.
|
Gu, Y.,
K. Kuida,
H. Tsutsui,
G. Ku,
K. Hsiao,
M. A. Fleming,
N. Hayashi,
K. Higashino,
H. Okamura,
K. Nakanishi,
M. Kurimoto,
T. Tanimoto,
R. A. Flavell,
V. Sato,
M. W. Harding,
D. J. Livingston, and M. S. Su.
1997.
Activation of interferon- inducing factor mediated by interleukin-1 converting enzyme.
Science
275:206-209[Abstract/Free Full Text].
|
| 18.
|
Hoshino, T.,
R. H. Wiltrout, and H. A. Young.
1999.
IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response.
J. Immunol.
162:5070-5077[Abstract/Free Full Text].
|
| 19.
|
Kapur, V.,
M. W. Majesky,
L. Li,
R. A. Black, and J. M. Musser.
1993.
Cleavage of interleukin 1 (IL-1 ) precursor to produce active IL-1 by a conserved extracellular cysteine protease from Streptococcus pyogenes.
Proc. Natl. Acad. Sci. USA
90:7676-7680[Abstract/Free Full Text].
|
| 20.
|
Kawakami, K.,
M. H. Qureshi,
T. Zhang,
H. Okamura,
M. Kurimoto, and A. Saito.
1997.
IL-18 protects mice against pulmonary and disseminated infection with Cryptococcus neoformans by introducing IFN- production.
J. Immunol.
159:5528-5534[Abstract].
|
| 21.
|
Kohno, K.,
J. Kataoka,
T. Ohtsuki,
Y. Suemoto,
I. Okamoto,
M. Usui,
M. Ikeda, and M. Kurimoto.
1997.
IFN- -inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12.
J. Immunol.
158:1541-1550[Abstract].
|
| 22.
|
Kremer, L.,
L. Dupré,
I. Wolowczuk, and C. Locht.
1999.
In vivo immunomodulation following intradermal injection with DNA encoding IL-18.
J. Immunol.
163:3226-3231[Abstract/Free Full Text].
|
| 23.
|
Kuida, K.,
J. A. Lippke,
M. W. Harding,
D. J. Livingston,
M. S. Su, and R. A. Flavell.
1995.
Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme.
Science
267:2000-2003[Abstract/Free Full Text].
|
| 24.
|
Li, P.,
H. Allen,
S. Banerjee,
S. Franklin,
L. Herzog,
C. Johnston,
J. McDowell,
M. Paskind,
L. Rodman,
J. Salfeld,
E. Towne,
D. Tracey,
S. Wardwell,
F. Y. Wei,
W. Wong, et al.
1995.
Mice deficient in IL-1 -converting enzyme are defective in production of mature IL-1 and resistant to endotoxic shock.
Cell
80:410-411.
|
| 25.
|
Mencacci, A.,
E. Cenci,
F. Bistoni,
A. Bacci,
G. Del Sero,
C. Montagnoli,
C. Fè d'Ostiani, and L. Romani.
1998.
Specific and non-specific immunity to Candida albicans: a lesson from genetically modified animals.
Res. Immunol.
149:352-361[CrossRef][Medline].
|
| 26.
|
Mencacci, A.,
E. Cenci,
G. Del Sero,
C. Fè d'Ostiani,
C. Montagnoli,
A. Bacci,
F. Bistoni,
V. F. J. Quesniaux,
B. Ryffel, and L. Romani.
1998.
Defective costimulation and impaired Th1 development in tumor necrosis factor/lymphotoxin- double-deficient mice infected with Candida albicans.
Int. Immunol.
10:37-48[Abstract/Free Full Text].
|
| 27.
|
Mencacci, A.,
E. Cenci,
G. Del Sero,
C. Fè d'Ostiani,
P. Mosci,
G. Trinchieri,
L. Adorini, and L. Romani.
1998.
IL-10 is required for development of protective CD4+ T helper type 1 cell responses to Candida albicans.
J. Immunol.
161:6228-6237[Abstract/Free Full Text].
|
| 28.
|
Mencacci, A.,
E. Cenci,
R. Spaccapelo,
L. Tonnetti,
L. Romani,
P. Puccetti, and F. Bistoni.
1995.
Rationale for cytokine and anti-cytokine therapy of Candida albicans infection.
J. Mycol. Med.
5:25-30.
|
| 29.
|
Monteleone, G.,
F. Trapasso,
T. Parello,
L. Biancone,
A. Stella,
R. Iuliano,
F. Luzza,
A. Fusco, and F. Pallone.
1999.
Bioactive IL-18 expression is up-regulated in Crohn's disease.
J. Immunol.
163:143-147[Abstract/Free Full Text].
|
| 30.
|
Odds, F. C.
1988.
Candida and candidosis, 2nd ed.
Baillière-Tindall, London, United Kingdom.
|
| 31.
|
Okamura, H.,
H. Tsutsui,
S. Kashiwamura,
T. Yoshimoto, and K. Nakanishi.
1998.
Interleukin-18: a novel cytokine that augments both innate and acquired immunity.
Adv. Immunol.
70:281-312[Medline].
|
| 32.
|
Okamura, H.,
H. Tsutsui,
T. Komatsu,
M. Yutsudo,
A. Hakura,
T. Tanimoto,
K. Torigoe,
T. Okura,
Y. Nukada,
K. Hattori,
K. Akita,
M. Namba,
F. Tanabe,
K. Konishi,
S. Fukuda, and M. Kurimoto.
1995.
Cloning of a new cytokine that induces IFN- production by T cells.
Nature
378:88-91[CrossRef][Medline].
|
| 33.
|
Oshikawa, K.,
F. Shi,
A. L. Rakhmilevich,
P. M. Sondel,
D. M. Mahvi, and N. Yang.
1999.
Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18 and IL-1 converting enzyme cDNA.
Proc. Natl. Acad. Sci. USA
96:13351-13356[Abstract/Free Full Text].
|
| 34.
|
Pecyk, R. A.,
E. B. Fraser-Smith, and T. R. Matthews.
1989.
Efficacy of interleukin-1 against systemic Candida albicans infections in normal and immunosuppressed mice.
Infect. Immun.
57:3257-3258[Abstract/Free Full Text].
|
| 35.
|
Puccetti, P.,
L. Romani, and F. Bistoni.
1995.
A Th1-Th2-like switch in candidiasis: new perspectives for therapy.
Trends Microbiol.
3:237-240[CrossRef][Medline].
|
| 36.
|
Qureshi, M. H.,
T. Zhang,
Y. Koguchi,
K. Nakashima,
H. Okamura,
M. Kurimoto, and K. Kawakami.
1999.
Combined effects of IL-12 and IL-18 on the clinical course and local cytokine production in murine pulmonary infection with Cryptococcus neoformans.
Eur. J. Immunol.
29:643-649[CrossRef][Medline].
|
| 37.
|
Robinson, D.,
K. Shibuya,
A. Mui,
F. Zonin,
E. Murphy,
T. Sana,
S. B. Hartley,
S. Menon,
R. Kastelein,
F. Bazan, and A. O'Garra.
1997.
IGIF does not drive Th1 development but synergizes with IL-12 for interferon- production and activates IRAK and NF B.
Immunity
7:571-581[CrossRef][Medline].
|
| 38.
|
Romani, L.
1997.
The T cell response to fungi.
Curr. Opin. Immunol.
9:484-490[CrossRef][Medline].
|
| 39.
|
Romani, L.
1999.
Immunity to Candida albicans: Th1, Th2 and beyond.
Curr. Opin. Microbiol.
2:363-367[CrossRef][Medline].
|
| 40.
|
Romani, L.,
A. Mencacci,
E. Cenci,
G. Del Sero,
F. Bistoni, and P. Puccetti.
1997.
An immunoregulatory role for neutrophils in CD4+ T helper subset selection in mice with candidiasis.
J. Immunol.
158:2356-2362[Abstract].
|
| 41.
|
Romani, L.,
A. Mencacci,
E. Cenci,
R. Spaccapelo,
G. Del Sero,
I. Nicoletti,
G. Trinchieri,
F. Bistoni, and P. Puccetti.
1997.
Neutrophil production of IL-12 and IL-10 in candidiasis and efficacy of IL-12 therapy in neutropenic mice.
J. Immunol.
158:5349-5356[Abstract].
|
| 42.
|
Romani, L.,
A. Mencacci,
E. Cenci,
R. Spaccapelo,
P. Mosci,
P. Puccetti, and F. Bistoni.
1993.
CD4+ subset expression in murine candidiasis. Th responses correlate directly with genetically determined susceptibility or vaccine-induced resistance.
J. Immunol.
150:925-931[Abstract].
|
| 43.
|
Romani, L.,
A. Mencacci,
E. Cenci,
R. Spaccapelo,
C. Toniatti,
P. Puccetti,
F. Bistoni, and V. Poli.
1996.
Impaired neutrophil response and CD4+ T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans.
J. Exp. Med.
183:1345-1355[Abstract/Free Full Text].
|
| 44.
|
Romani, L.,
A. Mencacci,
L. Tonnetti,
R. Spaccapelo,
E. Cenci,
P. Puccetti,
S. F. Wolf, and F. Bistoni.
1994.
IL-12 is both required and prognostic in vivo for T helper type 1 differentiation in murine candidiasis.
J. Immunol.
152:5167-5175.
|
| 45.
|
Romani, L.,
A. Mencacci,
L. Tonnetti,
R. Spaccapelo,
E. Cenci,
S. Wolf,
P. Puccetti, and F. Bistoni.
1994.
Interleukin-12 but not interferon- production correlates with induction of T helper type-1 phenotype in murine candidiasis.
Eur. J. Immunol.
24:909-915[Medline].
|
| 46.
|
Romani, L.,
P. Puccetti, and F. Bistoni.
1996.
Biological role of Th cell subsets in candidiasis.
Chem. Immunol.
63:115-137[Medline].
|
| 47.
|
Rothe, H.,
N. Jenkins,
N. Copeland, and H. Kolb.
1997.
Active stage of autoimmune diabetes is associated with the expression of a novel cytokine, IGIF, which is located near Idd2.
J. Clin. Investig.
99:469-474[Medline].
|
| 48.
|
Spaccapelo, R.,
L. Romani,
L. Tonnetti,
E. Cenci,
A. Mencacci,
R. Tognellini,
S. G. Reed,
P. Puccetti, and F. Bistoni.
1995.
TGF- is important in determining the in vivo susceptibility or resistance in mice infected with Candida albicans.
J. Immunol.
155:1349-1360[Abstract].
|
| 49.
|
Takeda, K.,
H. Tsutsui,
T. Yoshimoto,
O. Adachi,
N. Yoshida,
T. Kishimoto,
H. Okamura,
K. Nakanishi, and S. Akira.
1998.
Defective NK cell activity and Th1 response in IL-18 deficient mice.
Immunity
8:383-390[CrossRef][Medline].
|
| 50.
|
Thornberry, N. A.,
H. G. Bull,
J. R. Calaycay,
K. T. Chapman,
A. D. Howard,
M. J. Kostura,
D. K. Miller,
S. M. Molineaux,
J. R. Weidner,
J. Aunins,
K. O. Elliston,
J. M. Ayala,
F. J. Casano,
J. Chin,
G. J. F. Ding, et al.
1992.
A novel heterodimeric cysteine protease is required for interleukin-1 processing in monocytes.
Nature
356:768-774[CrossRef][Medline].
|
| 51.
|
Thornberry, N. A.,
T. A. Rano,
E. P. Peterson,
D. M. Rasper,
T. Timkey,
M. Garcia-Calvo,
V. M. Houtzager,
P. A. Nordstrom,
S. Roy,
J. P. Vaillancourt,
K. T. Chapman, and D. W. Nicholson.
1997.
A combinatorial approach defines specificities of members of the caspase family and granzyme B: functional relationships established for key mediators of apoptosis.
J. Biol. Chem.
272:17907-17911[Abstract/Free Full Text].
|
| 52.
|
Wei, X.,
B. P. Leung,
W. Niedbala,
D. Piedrafita,
G. Feng,
M. Sweet,
L. Dobbie,
A. J. H. Smith, and F. Y. Liew.
1999.
Altered immune responses and susceptibility to Leishmania major and Staphylococcus aureus infection in IL-18-deficient mice.
J. Immunol.
163:2821-2828[Abstract/Free Full Text].
|
| 53.
|
Wewers, M. D.,
H. A. Dare,
A. V. Winnard,
J. M. Parker, and D. K. Miller.
1997.
IL-1 -converting enzyme (ICE) is present and functional in human alveolar macrophages: macrophage IL-1 release limitation is ICE independent.
J. Immunol.
159:5964-5972[Abstract].
|
| 54.
|
Xu, D.,
W. L. Chan,
B. P. Leung,
D. Hunter,
K. Schulz,
R. W. Carter,
I. B. McInnes,
J. H. Robinson, and F. Y. Liew.
1998.
Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 but not Th2 cells.
J. Exp. Med.
188:1485-1492[Abstract/Free Full Text].
|
| 55.
|
Yoshimoto, T.,
K. Takeda,
T. Tanaka,
K. Ohkusu,
S. Kashiwamura,
H. Okamura,
S. Akira, and K. Nakanishi.
1998.
IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN- production.
J. Immunol.
161:3400-3407[Abstract/Free Full Text].
|
| 56.
|
Zhang, T.,
K. Kawakami,
M. H. Qureshi,
H. Okamura,
M. Kurimoto, and A. Saito.
1997.
Interleukin-12 (IL-12) and IL-18 synergistically induce the fungicidal activity of murine peritoneal exudate cells against Cryptococcus neoformans through production of gamma interferon by natural killer cells.
Infect. Immun.
65:3594-3599[Abstract].
|
Infection and Immunity, September 2000, p. 5126-5131, Vol. 68, No. 9
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Omoto, Y., Tokime, K., Yamanaka, K., Habe, K., Morioka, T., Kurokawa, I., Tsutsui, H., Yamanishi, K., Nakanishi, K., Mizutani, H.
(2006). Human Mast Cell Chymase Cleaves Pro-IL-18 and Generates a Novel and Biologically Active IL-18 Fragment. J. Immunol.
177: 8315-8319
[Abstract]
[Full Text]
-
Drennan, M. B., Stijlemans, B., Van Den Abbeele, J., Quesniaux, V. J., Barkhuizen, M., Brombacher, F., De Baetselier, P., Ryffel, B., Magez, S.
(2005). The Induction of a Type 1 Immune Response following a Trypanosoma brucei Infection Is MyD88 Dependent. J. Immunol.
175: 2501-2509
[Abstract]
[Full Text]
-
Bellocchio, S., Montagnoli, C., Bozza, S., Gaziano, R., Rossi, G., Mambula, S. S., Vecchi, A., Mantovani, A., Levitz, S. M., Romani, L.
(2004). The Contribution of the Toll-Like/IL-1 Receptor Superfamily to Innate and Adaptive Immunity to Fungal Pathogens In Vivo. J. Immunol.
172: 3059-3069
[Abstract]
[Full Text]
-
Gracie, J. A., Robertson, S. E., McInnes, I. B.
(2003). Interleukin-18. J. Leukoc. Biol.
73: 213-224
[Abstract]
[Full Text]
-
Joshi, V. D., Kalvakolanu, D. V., Hebel, J. R., Hasday, J. D., Cross, A. S.
(2002). Role of Caspase 1 in Murine Antibacterial Host Defenses and Lethal Endotoxemia. Infect. Immun.
70: 6896-6903
[Abstract]
[Full Text]
-
Joshi, V. D., Kalvakolanu, D. V., Hasday, J. D., Hebel, R. J., Cross, A. S.
(2002). IL-18 Levels and the Outcome of Innate Immune Response to Lipopolysaccharide: Importance of a Positive Feedback Loop with Caspase-1 in IL-18 Expression. J. Immunol.
169: 2536-2544
[Abstract]
[Full Text]
-
Stuyt, R. J. L., Netea, M. G., Verschueren, I., Fantuzzi, G., Dinarello, C. A., Van der Meer, J. W. M., Kullberg, B. J.
(2002). Role of Interleukin-18 in Host Defense against Disseminated Candida albicans Infection. Infect. Immun.
70: 3284-3286
[Abstract]
[Full Text]